AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00593164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling with ThermoSuit with Magnesium Sulfate Infusion
Description: Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
Study NCT00593164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooling with ThermoSuit with Normal Saline Infusion
Description: Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
Study NCT02883322 — intervention group
Intervention type: OTHER
Intervention: Cross cultural adaptation of patient reported outcomes (PRO)
Description: Process used to adapt a questionnaire from one cultural setting to another
Study NCT01747161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulin toxin
Description: 50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
Study NCT01747161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological water
Description: 3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
Study NCT01013675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures
Study NCT01013675 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in egg (influvac ®)
Study NCT01445639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
Study NCT01445639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: as placebo
Study NCT03679130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training
Description: EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
Study NCT03679130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational counseling supported by health technology
Description: MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
Study NCT03756389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-010
Description: Safety and efficacy of BMX-010 in topical treatment of rosacea.
Study NCT00839228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: 100mg o bd for 3 months
Study NCT00839228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet bd for 3 months
Study NCT01824446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled SPD602 (FBS0701, SSP-004184)
Description: A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
Study NCT01033643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
Study NCT01033643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-3614
Description: Participants were administered dose matched placebo tablets according to randomization.
Study NCT02442414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5209
Description: Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
Study NCT01456663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT00536666 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iron oligosaccharide
Study NCT04559464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AeriSeal
Description: The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
Study NCT03892850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse prescription
Description: Pharmacological nurse prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
Study NCT03892850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical prescription
Description: Pharmacological medical prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
Study NCT03927365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation from a salt particle inhaler with or without content
Description: Inhalation from inhaler with (active) or without (placebo) content
Study NCT03927365 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation from a salt particle inhaler with or without content
Description: Inhalation from inhaler with (active) or without (placebo) content
Study NCT04484909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given IT
Study NCT04484909 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00027612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: IV
Study NCT00027612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV
Study NCT00027612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02091063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Description: All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
Study NCT03449459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral probiotics
Description: Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.~Subjects will take conventional therapy at the same time.
Study NCT04559464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zephyr Valves
Description: The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
Study NCT04854317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic gastroplasty
Description: Endoscopic Gastroplasty
Study NCT03907891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational social support from nurse
Description: A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
Study NCT03907891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational social support from nurse with additional support from significant other
Description: A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
Study NCT03907891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
Study NCT03449459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosol inhaled amikacin
Description: 0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time.
Study NCT03449459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combined vaccination
Description: Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.~The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.~Subjects will take conventional therapy at the same time.
Study NCT00185484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Description: Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
Study NCT03498040 — intervention group
Intervention type: OTHER
Intervention: Study of the occurrence of Carcinoid Heart Disease
Description: Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, ...) biological parameters (urinary 5HIAA, NT-ProBNP ...) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease.
Study NCT01511536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form:solution Route of administration: injection
Study NCT01511536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Pharmaceutical form:tablets Route of administration: oral
Study NCT01511536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: Route of administration: oral
Study NCT02357758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic Prophylaxis
Description: Approved clinical dosage or antibiotics
Study NCT00950053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles decompression & debridement
Description: Surgical intervention
Study NCT00950053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles decompression and debridement with FHL transfer
Description: surgical intervention
Study NCT02703532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-CITE Education Program
Description: CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete.
Study NCT02703532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education
Description: Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
Study NCT02703532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Description: Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete.
Study NCT02703532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-Induced Movement Therapy (CIMT)
Description: Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete.
Study NCT03941301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
Study NCT03941301 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light therapy
Description: Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
Study NCT04314128 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TOS and TCD
Description: TOS: Transorbital sonography TCD: Transcranial Doppler
Study NCT03076801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choral Singing
Description: In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
Study NCT02046642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal rest in left lateral position
Description: After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
Study NCT02046642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal rest in right lateral position
Description: After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
Study NCT02685293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
Study NCT02685293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
Study NCT04285086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg
Study NCT04285086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagrelide
Description: Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement
Study NCT01174992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evicel
Description: EVICEL is a human plasma derived fibrin sealant
Study NCT01174992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sutures only
Description: Standard of care
Study NCT00031447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Oral suspension 300 mg/m\^2/dose, 3 times per day (TID), for 6 months.
Study NCT00031447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to oral acyclovir suspension in appearance and taste.
Study NCT01161160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' GSK2340274A (two different formulations)
Description: Intramuscular injection
Study NCT01161160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' - GSK2340272A
Description: Intramuscular injection
Study NCT01188122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnapnoGuard 100
Description: Respiratory guard system during mechanical ventilation
Study NCT00554164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (R-)CHOP protocol
Description: Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
Study NCT00554164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-ALL protocol
Description: Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
Study NCT00554164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (R-)CHOP protocol
Description: Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
Study NCT00554164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (R-)CHOP protocol
Description: Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
Study NCT02622425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin
Study NCT02622425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PD01
Description: Carotenoid-producing Bacillus strain PD01
Study NCT02695043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RRTBIMS
Description: TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
Study NCT02695043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Multicultural Educational Program for TBI (MMEPT)
Study NCT02634645 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic eradication therapies (EET)
Description: Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
Study NCT02634645 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: The esophagus is surgically removed
Study NCT02634645 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemical substances are used to treat cancer
Study NCT02634645 — intervention group
Intervention type: RADIATION
Intervention: Radiation
Description: Cancer cells are destroyed by radiation therapy.
Study NCT01819415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-VEGF plus AREDS-2
Description: Omega-3 metabolites supplementation
Study NCT01819415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF plus AREDS-1
Description: Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.